These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 21715435

  • 1. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A, German Competence Network for HIV/AIDS Coordinators.
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [Abstract] [Full Text] [Related]

  • 2. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, Sarfo MA, Khoo S, Owen A, Chadwick DR.
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [Abstract] [Full Text] [Related]

  • 3. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
    Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJ.
    Ther Drug Monit; 2013 Feb; 35(1):78-83. PubMed ID: 23172109
    [Abstract] [Full Text] [Related]

  • 4. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA.
    PLoS One; 2022 Feb; 17(3):e0260872. PubMed ID: 35235559
    [Abstract] [Full Text] [Related]

  • 5. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [Abstract] [Full Text] [Related]

  • 6. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
    Powers V, Ward J, Gompels M.
    HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
    [Abstract] [Full Text] [Related]

  • 7. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [Abstract] [Full Text] [Related]

  • 8. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T, O'Brien J, Song JC, Patel R, Winslow DL.
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [Abstract] [Full Text] [Related]

  • 9. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [Abstract] [Full Text] [Related]

  • 10. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.
    Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
    [Abstract] [Full Text] [Related]

  • 11. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [Abstract] [Full Text] [Related]

  • 12. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
    Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP.
    J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
    [Abstract] [Full Text] [Related]

  • 13. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
    Rohrbacher M, Kirchhof A, Geisslinger G, Lötsch J.
    Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
    Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP, Adult AIDS Clinical Trials Group Study.
    Clin Infect Dis; 2006 Feb 01; 42(3):401-7. PubMed ID: 16392089
    [Abstract] [Full Text] [Related]

  • 15. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.
    Eur J Clin Pharmacol; 2012 Mar 01; 68(3):267-71. PubMed ID: 21901344
    [Abstract] [Full Text] [Related]

  • 16. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
    Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, García MJ.
    Antimicrob Agents Chemother; 2009 Jul 01; 53(7):2791-8. PubMed ID: 19433561
    [Abstract] [Full Text] [Related]

  • 17. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P, Dillingham R, Beauharnais CA, Kashuba AD, Rezk NL, Fitzgerald DW, Pape JW, Haas DW.
    J Infect Dis; 2009 Sep 15; 200(6):955-64. PubMed ID: 19659438
    [Abstract] [Full Text] [Related]

  • 18. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ.
    AIDS Res Hum Retroviruses; 2018 Nov 15; 34(11):982-992. PubMed ID: 29973058
    [Abstract] [Full Text] [Related]

  • 19. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS, To KW, Lee MP, Wong NS, Chan DP, Li PC, Cheung SW, Chan RC.
    Int J STD AIDS; 2014 Mar 15; 25(3):193-200. PubMed ID: 23970651
    [Abstract] [Full Text] [Related]

  • 20. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A, German Competence Network for HIV/AIDS.
    J Antimicrob Chemother; 2008 Apr 15; 61(4):914-8. PubMed ID: 18281305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.